{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:06:31Z","timestamp":1782821191676,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008436","name":"National Foundation for Medical Research and Innovation","doi-asserted-by":"publisher","award":["Cure4CF"],"award-info":[{"award-number":["Cure4CF"]}],"id":[{"id":"10.13039\/100008436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["0006007079"],"award-info":[{"award-number":["0006007079"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.tube.2023.102390","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T20:00:19Z","timestamp":1690228819000},"page":"102390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Deferiprone-gallium-protoporphyrin (IX): A promising treatment modality against Mycobacterium abscessus"],"prefix":"10.1016","volume":"142","author":[{"given":"Sholeh","family":"Feizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Nepal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare M.","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkis J.","family":"Psaltis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-John","family":"Wormald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Vreugde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tube.2023.102390_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"issue":"Suppl 1","key":"10.1016\/j.tube.2023.102390_bib2","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.tube.2023.102390_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/thx.2005.049247","article-title":"Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation","volume":"61","author":"Chalermskulrat","year":"2006","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.tube.2023.102390_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1513\/AnnalsATS.201503-173OC","article-title":"The burden of pulmonary nontuberculous mycobacterial disease in the United States","volume":"12","author":"Strollo","year":"2015","journal-title":"Annals of the American Thoracic Society"},{"issue":"11","key":"10.1016\/j.tube.2023.102390_bib5","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1513\/AnnalsATS.201605-344BC","article-title":"Relapse versus reinfection of Mycobacterium avium complex pulmonary disease. Patient characteristics and macrolide susceptibility","volume":"13","author":"Boyle","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"issue":"4","key":"10.1016\/j.tube.2023.102390_bib6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.tube.2023.102390_bib7","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2023.102390_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02643-18","article-title":"Iron\/heme metabolism-targeted gallium (III) nanoparticles are active against extracellular and intracellular Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"63","author":"Choi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2023.102390_bib9","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1021\/acs.molpharmaceut.7b01036","article-title":"In vitro efficacy of free and nanoparticle formulations of gallium (III) meso-tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and gallium biodistribution in mice","volume":"15","author":"Choi","year":"2018","journal-title":"Mol Pharm"},{"issue":"1\u20132","key":"10.1016\/j.tube.2023.102390_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tube.2003.08.012","article-title":"Iron, mycobacteria and tuberculosis","volume":"84","author":"Ratledge","year":"2004","journal-title":"Tuberculosis"},{"issue":"15","key":"10.1016\/j.tube.2023.102390_bib11","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1128\/JB.181.15.4443-4451.1999","article-title":"Iron acquisition and metabolism by mycobacteria","volume":"181","author":"De Voss","year":"1999","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.tube.2023.102390_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tube.2015.01.004","article-title":"Iron acquisition strategies in mycobacteria","volume":"95","author":"Fang","year":"2015","journal-title":"Tuberculosis"},{"issue":"6","key":"10.1016\/j.tube.2023.102390_bib13","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3390\/ijms22062876","article-title":"Recent advances in iron chelation and gallium-based therapies for antibiotic resistant bacterial infections","volume":"22","author":"Vinuesa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tube.2023.102390_bib14","series-title":"International forum of allergy & rhinology","article-title":"Mind \u201cDe GaPP\u201d: in vitro efficacy of deferiprone and gallium\u2010protoporphyrin against Staphylococcus aureus biofilms","author":"Richter","year":"2016"},{"issue":"6","key":"10.1016\/j.tube.2023.102390_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00481-17","article-title":"A topical hydrogel with deferiprone and gallium-protoporphyrin targets bacterial iron metabolism and has antibiofilm activity","volume":"61","author":"Richter","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2023.102390_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fcimb.2017.00280","article-title":"Deferiprone and gallium-protoporphyrin have the capacity to potentiate the activity of antibiotics in Staphylococcus aureus small colony variants","volume":"7","author":"Richter","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.tube.2023.102390_bib17","series-title":"Clinical and laboratory standards institute methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approve Standard M7-A7","author":"Clsi","year":"2006"},{"key":"10.1016\/j.tube.2023.102390_bib18","article-title":"Colloidal silver combating pathogenic Pseudomonas aeruginosa and MRSA in chronic rhinosinusitis","volume":"202","author":"Sholeh Feizi","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"4","key":"10.1016\/j.tube.2023.102390_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.pathol.2021.08.014","article-title":"Silver nanoparticles as a bioadjuvant of antibiotics against biofilm-mediated infections with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in chronic rhinosinusitis patients","volume":"54","author":"Feizi","year":"2022","journal-title":"Pathology"},{"key":"10.1016\/j.tube.2023.102390_bib20","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical","year":"2006"},{"key":"10.1016\/j.tube.2023.102390_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2021.112606","article-title":"Green synthesized colloidal silver is devoid of toxic effects on primary human nasal epithelial cells in vitro","volume":"157","author":"Feizi","year":"2021","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.tube.2023.102390_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/s10534-023-00494-w","article-title":"Colloidal silver against macrophage infections and biofilms of atypical mycobacteria","author":"Feizi","year":"2023","journal-title":"Biometals"},{"issue":"1","key":"10.1016\/j.tube.2023.102390_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pdpdt.2014.12.004","article-title":"Effects of divalent cations, EDTA and chitosan on the uptake and photoinactivation of Escherichia coli mediated by cationic and anionic porphyrins","volume":"12","author":"Gsponer","year":"2015","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"10","key":"10.1016\/j.tube.2023.102390_bib24","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.3390\/pharmaceutics14102124","article-title":"Gallium protoporphyrin liquid crystalline lipid nanoparticles: a third-generation photosensitizer against Pseudomonas aeruginosa biofilms","volume":"14","author":"Awad","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.tube.2023.102390_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.tube.2023.102390_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2958.1999.01175.x","article-title":"Non\u2010iron metalloporphyrins: potent antibacterial compounds that exploit haem\/Hb uptake systems of pathogenic bacteria","volume":"31","author":"Stojiljkovic","year":"1999","journal-title":"Mol Microbiol"},{"issue":"3","key":"10.1016\/j.tube.2023.102390_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10534-006-9032-0","article-title":"Intracellular metalloporphyrin metabolism in Staphylococcus aureus","volume":"20","author":"Reniere","year":"2007","journal-title":"Biometals"},{"key":"10.1016\/j.tube.2023.102390_bib28","article-title":"Advancement of gallium and gallium-based compounds as antimicrobial agents","volume":"10","author":"Li","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"10.1016\/j.tube.2023.102390_bib29","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1128\/AAC.00778-12","article-title":"In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii","volume":"56","author":"de L\u00e9s\u00e9leuc","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.tube.2023.102390_bib30","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1128\/AAC.01197-12","article-title":"Antibacterial activities of iron chelators against common nosocomial pathogens","volume":"56","author":"Thompson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.tube.2023.102390_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1183\/09031936.00154006","article-title":"Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis","volume":"30","author":"Reid","year":"2007","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.tube.2023.102390_bib32","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1128\/AAC.00331-15","article-title":"Gallium compounds exhibit potential as new therapeutic agents against Mycobacterium abscessus","volume":"59","author":"Abdalla","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.tube.2023.102390_bib33","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/acsinfecdis.0c00113","article-title":"Gallium porphyrin and gallium nitrate synergistically inhibit mycobacterial species by targeting different aspects of iron\/heme metabolism","volume":"6","author":"Choi","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.tube.2023.102390_bib34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979223000884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979223000884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:46:42Z","timestamp":1761468402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979223000884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"alternative-id":["S1472979223000884"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2023.102390","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deferiprone-gallium-protoporphyrin (IX): A promising treatment modality against Mycobacterium abscessus","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2023.102390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102390"}}